Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 30;10(11):e005970. doi: 10.1136/jitc-2022-005970

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Response to (re)immunotherapy and management of immune-related MG. (A) Low-powered magnification (×4) H&E stain of the thymic lesion. The yellow arrows indicate the thymic lesion. (B) Representative CT images of patients during the treatment (from the baseline to ICI rechallenge). The yellow arrows indicate the thymic lesion. (C), Change in levels of blood indicators of cardiac and liver damage. The arrows with different color represent the indicated stage of the treatment. ALT, alanine aminotransferase; AST, aspartate transaminase; cTnT, cardiac troponin T; CK-MB, creatine kinase-MB; ICI, immune checkpoint inhibitor; MG, myasthenia gravis.